Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Matthew R. Deshotels; Salim S. Virani; Christie M. Ballantyne

doi:10.1007/s11886-021-01545-9

Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Matthew R. Deshotels, Salim S. Virani, Christie M. Ballantyne

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

Purpose of Review: The 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of Secondary Prevention Lipid Performance Measures removed low-density lipoprotein cholesterol (LDL-C) assessment as a performance measure. This review discusses the evidence supporting the importance of lipid monitoring in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Recent Findings: The 2018 AHA/ACC Multisociety cholesterol guideline (as did the 2013 guideline) recommends a lipid panel after initiating lipid-lowering therapy to monitor adherence and medication efficacy. The 2018 guideline also recommends adding nonstatin therapy in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy. Summary: The removal of LDL-C monitoring as a performance measure is not consistent with the 2018 cholesterol guidelines. Given the importance of monitoring lipid-lowering medication efficacy and adherence and optimally reducing LDL-C in very-high-risk patients with additional evidence-based nonstatin therapy, LDL-C assessment after initiating lipid-lowering therapy should be reinstated as a performance measure for patients with ASCVD.

Original language	English
Article number	116
Journal	Current Cardiology Reports
Volume	23
Issue number	9
DOIs	https://doi.org/10.1007/s11886-021-01545-9
Publication status	Published - Sept 2021
Externally published	Yes

Keywords

Atherosclerosis
Low-density lipoprotein-C (LDL-C)
Performance measure
Statin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11886-021-01545-9

Cite this

@article{0059723b8d594bf9bb7bb0dcb0cea50c,

title = "Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?",

abstract = "Purpose of Review: The 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of Secondary Prevention Lipid Performance Measures removed low-density lipoprotein cholesterol (LDL-C) assessment as a performance measure. This review discusses the evidence supporting the importance of lipid monitoring in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Recent Findings: The 2018 AHA/ACC Multisociety cholesterol guideline (as did the 2013 guideline) recommends a lipid panel after initiating lipid-lowering therapy to monitor adherence and medication efficacy. The 2018 guideline also recommends adding nonstatin therapy in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy. Summary: The removal of LDL-C monitoring as a performance measure is not consistent with the 2018 cholesterol guidelines. Given the importance of monitoring lipid-lowering medication efficacy and adherence and optimally reducing LDL-C in very-high-risk patients with additional evidence-based nonstatin therapy, LDL-C assessment after initiating lipid-lowering therapy should be reinstated as a performance measure for patients with ASCVD.",

keywords = "Atherosclerosis, Low-density lipoprotein-C (LDL-C), Performance measure, Statin",

author = "Deshotels, {Matthew R.} and Virani, {Salim S.} and Ballantyne, {Christie M.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2021",

month = sep,

doi = "10.1007/s11886-021-01545-9",

language = "English",

volume = "23",

journal = "Current Cardiology Reports",

issn = "1523-3782",

publisher = "Current Medicine Group",

number = "9",

}

TY - JOUR

T1 - Lipid Monitoring After Initiation of Lipid-Lowering Therapies

T2 - Return of Performance Measures?

AU - Deshotels, Matthew R.

AU - Virani, Salim S.

AU - Ballantyne, Christie M.

PY - 2021/9

Y1 - 2021/9

N2 - Purpose of Review: The 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of Secondary Prevention Lipid Performance Measures removed low-density lipoprotein cholesterol (LDL-C) assessment as a performance measure. This review discusses the evidence supporting the importance of lipid monitoring in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Recent Findings: The 2018 AHA/ACC Multisociety cholesterol guideline (as did the 2013 guideline) recommends a lipid panel after initiating lipid-lowering therapy to monitor adherence and medication efficacy. The 2018 guideline also recommends adding nonstatin therapy in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy. Summary: The removal of LDL-C monitoring as a performance measure is not consistent with the 2018 cholesterol guidelines. Given the importance of monitoring lipid-lowering medication efficacy and adherence and optimally reducing LDL-C in very-high-risk patients with additional evidence-based nonstatin therapy, LDL-C assessment after initiating lipid-lowering therapy should be reinstated as a performance measure for patients with ASCVD.

AB - Purpose of Review: The 2015 American College of Cardiology (ACC)/American Heart Association (AHA) Focused Update of Secondary Prevention Lipid Performance Measures removed low-density lipoprotein cholesterol (LDL-C) assessment as a performance measure. This review discusses the evidence supporting the importance of lipid monitoring in the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Recent Findings: The 2018 AHA/ACC Multisociety cholesterol guideline (as did the 2013 guideline) recommends a lipid panel after initiating lipid-lowering therapy to monitor adherence and medication efficacy. The 2018 guideline also recommends adding nonstatin therapy in very-high-risk ASCVD patients with LDL-C ≥70 mg/dL despite maximally tolerated statin therapy. Summary: The removal of LDL-C monitoring as a performance measure is not consistent with the 2018 cholesterol guidelines. Given the importance of monitoring lipid-lowering medication efficacy and adherence and optimally reducing LDL-C in very-high-risk patients with additional evidence-based nonstatin therapy, LDL-C assessment after initiating lipid-lowering therapy should be reinstated as a performance measure for patients with ASCVD.

KW - Atherosclerosis

KW - Low-density lipoprotein-C (LDL-C)

KW - Performance measure

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85110466126&partnerID=8YFLogxK

U2 - 10.1007/s11886-021-01545-9

DO - 10.1007/s11886-021-01545-9

M3 - Review article

C2 - 34269897

AN - SCOPUS:85110466126

SN - 1523-3782

VL - 23

JO - Current Cardiology Reports

JF - Current Cardiology Reports

IS - 9

M1 - 116

ER -

Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this